Pages that link to "Item:Q3549405"
From MaRDI portal
The following pages link to Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates (Q3549405):
Displaying 17 items.
- Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates (Q419309) (← links)
- Adaptive Bayesian compound designs for dose finding studies (Q434557) (← links)
- Bayesian models and decision algorithms for complex early phase clinical trials (Q903294) (← links)
- Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials (Q1654244) (← links)
- Bayesian learning of dose-response parameters from a cohort under response-guided dosing (Q1681360) (← links)
- Individualized dosing for multiple ordered groups of patients (Q2320813) (← links)
- Clinical trials for personalized dose finding (Q2829305) (← links)
- Optimizing the concentration and bolus of a drug delivered by continuous infusion (Q2893431) (← links)
- A utility approach to individualized optimal dose selection using biomarkers (Q3299111) (← links)
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
- Risk-Group-Specific Dose Finding Based on an Average Toxicity Score (Q3576932) (← links)
- Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies (Q4690922) (← links)
- Patient-specific dose finding in phase I clinical trials (Q5036370) (← links)
- Patient-specific dose finding in seamless phase I/II clinical trials (Q5043686) (← links)
- Estimating individualized treatment rules with risk constraint (Q6047773) (← links)
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)
- Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers (Q6637080) (← links)
